Pharma Industry

Lawsuit demands retraction of report from July.

Feds say anticompetitive business practices shifted costs to vulnerable patients.

The pharmaceutical industry has increasingly taken aim at the program for growing costs, but is that accurate? American Hospital Association analysts offer this perspective.

By improving health outcomes and avoiding costly obesity-related complications, GLP-1s can significantly reduce the overall cost of health care.

Undermining access to biologics is not the answer.

In theory, patients should benefit from drug price discounts negotiated between drug companies and insurers. In reality, they don’t, and a potential solution is stalled in Congress.

How health care professionals can help close the awareness gap and support families to screen for type 1 diabetes

Savings in the future on 10 prescription drugs for taxpayers and Medicare patients.

Beneficiaries are projected to save $1.5 billion in out-of-pocket spending next year.

America's poorest seniors could soon find it much harder to get the medicines they need.

AAFP president weighs in on current issues in U.S. health care market.

The top news stories in medicine today.

Novo Nordisk says it is working to make more; FDA warns against too much of a good thing.

For some seniors living with chronic diseases, one particular reform may actually lead to higher out-of-pocket costs

Three largest pharmacy benefit manager executives testify in House Oversight Committee.

House Oversight Committee takes aim at pharmacy benefit managers.

PBMs counter that document is heavy on accusations but empty for evidence.

Some PBMs have ignored government compliance orders despite having two years to comply

The consolidation of health care is well underway, with PBMs making moves to keep and expand their control. But new models are emerging to offer hope for changing the health care industry for good.

How lawmakers can regulate PBMs.

Analysts ponder value, transparency and the effects of the Inflation Reduction Act.

Unpacking vaccine pricing: navigating policy, economics, and public health imperatives.

Rep. Greg Murphy, MD, discusses prior authorizations and other pending legislation in Washington.

Abortion and AI also in the mix at the national level.

Critics air concerns at White House roundtable as pharmacy benefit manager volley back.